BioPharma Dive June 24, 2024
Positive results in the HELIOS-B trial could support an expanded approval of Alnylam’s drug vutrisiran in transthyretin amyloidosis cardiomyopathy.
An experimental medicine helped people with a deadly heart disease stay out of the hospital and live longer in a closely watched clinical trial, a finding that could pave the way for a regulatory approval and help its developer, Alnylam Pharmaceuticals, rebound from a significant setback.
Trial data released Monday showed trial participants with the disease, transthyretin amyloidosis cardiomyopathy, and treated with Alnylam’s drug had a 28% lower risk of death from any cause or recurrent cardiovascular event, compared to those given a placebo. Alnylam said its drug was associated with a 33% risk reduction versus placebo among people who weren’t...
Today's Sponsors
Today's Sponsor